Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypothesis: how do JAK2-inhibitors work in myelofibrosis.

Leukemia research - 1 Sept 2009

Mesa Ruben, Gale Robert Peter

Abstract excerpt

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to JAK2 gene
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 19450878
DOI: 10.1016/j.leukres.2009.04.011

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypothesis: how do JAK2-inhibitors work in myelofibrosis.PMID 19450878Read ↗

How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.Semantic proximity Read ↗

How I treat myelofibrosis.Semantic proximity Read ↗

How I treat myelofibrosis after failure of JAK inhibitors.Semantic proximity Read ↗

Therapeutic potential of JAK2 inhibitorsSemantic proximity Read ↗

JAK2 inhibitors: what's the true therapeutic potential?Semantic proximity Read ↗

JAK2 inhibitors: are they the solution?Semantic proximity Read ↗

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?Semantic proximity Read ↗

JAK2 inhibitors in myelofibrosis.Semantic proximity Read ↗

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Semantic proximity Read ↗

Ruxolitinib. Bone marrow fibrosis: theory versus practice.Semantic proximity Read ↗

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.